Is risankizumab as needed administration a good option for patients with plaque psoriasis?

J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e713-e715. doi: 10.1111/jdv.18182. Epub 2022 May 5.

Authors

P Gisondi¹, M Maurelli¹, F Bellinato¹, G Girolomoni¹

Affiliation

¹ Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

PMID: 35470475
DOI: 10.1111/jdv.18182

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal
risankizumab

Grants and funding

ID 1833073 rif. 2020-1363/Fondazione Cariplo, Fondazione Veronesi, Impact of COVID19 infection on patients affected by inflammatory skin diseases on immunosuppressive therapies (COVISKIN)